Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Prostate Irreversible Electroporation Study

NCT: NCT06886321 · RECRUITING

NCT IDNCT06886321
StatusRECRUITING
Start Date2025-06-30
Completion2027-06-30
SponsorChinese University of Hong Kong (OTHER)
First posted
Last updated

Brief Summary

Conventional treatment options for localized prostate cancer include prostatectomy, radiotherapy and active surveillance. However, prostatectomy and radiotherapy carry certain degree of morbidity, including the risks of urinary incontinence, erectile dysfunction and injury to the structures in the proximity. Active surveillance carries the risk of disease progression and psychological distress to the patients. Focal therapy employs the concept of only destroying the significant lesion, resulting in disease cure and improved functional outcome. Among the different options of focal therapy, Irreversible electroporation has evolved over the past decades and can be a reliable treatment option. Our study aims at assess the safety and effectiveness of such treatment in prostate cancer management.

Frequently Asked Questions

What is Prostate Irreversible Electroporation Study?

Prostate Irreversible Electroporation Study is a clinical trial registered under NCT06886321. Current status: RECRUITING.

What is the status of NCT06886321?

The current status of NCT06886321 (Prostate Irreversible Electroporation Study) is: RECRUITING.

When did Prostate Irreversible Electroporation Study start?

Prostate Irreversible Electroporation Study started on 2025-06-30.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.